Amato

SYNAPS Dx Observes September as World Alzheimer’s Month and Healthy Aging Month: Celebrates Researchers, Providers and Patients

Retrieved on: 
Tuesday, September 26, 2023
Research, Mental Health, Nursing, Seniors, Neurology, Biotechnology, Managed Care, Consumer, Health, Science, DISCERN, Synaptic, Obesity, Depression, Software-defined, Diabetes, Hearing loss, Clinical Laboratory, Albert Einstein's brain, Risk, Brain, Dementia, Medicare, Gold standard, CLIA, HIV disease progression rates, Patient, Kool-Aid, Diagnosis, AD, Smoking, Autopsy, Amato, Pharmaceutical industry, Medical device, Medical imaging

The 2023 theme ‘Never too early, never too late’ highlights the need for an early and accurate diagnosis of AD and the importance of recognizing AD risk factors.

Key Points: 
  • The 2023 theme ‘Never too early, never too late’ highlights the need for an early and accurate diagnosis of AD and the importance of recognizing AD risk factors.
  • Awareness of risk reduction strategies is crucial, especially for those who are not yet showing symptoms.
  • A minimally invasive, 3mm skin punch biopsy , DISCERN can be administered in a primary care setting.
  • DISCERN assesses factors closely related to the formation of synaptic connections in the brain as well as the formation of amyloid plaque and abnormal tau.

SYNAPS Dx President & CEO, Frank Amato, Named Life Sciences CEO of the Year in Maryland Tech Council 2023 ICON Awards

Retrieved on: 
Tuesday, May 2, 2023
Science, Neurology, Biotechnology, Research, Managed Care, General Health, Health, Other Health, National Youth Icon Award, DISCERN, MTC, Software-defined, Multimedia, Dementia, Patient, Award, Diagnosis, AD, Amato, Pharmaceutical industry

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is thrilled to announce the Maryland Tech Council (MTC), one of the largest technology and life science trade associations in the U.S., has selected Frank Amato, CEO and president, Maryland-headquartered SDx, as the 2023 Life Sciences CEO of the Year at the ICON Awards.

Key Points: 
  • SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is thrilled to announce the Maryland Tech Council (MTC), one of the largest technology and life science trade associations in the U.S., has selected Frank Amato, CEO and president, Maryland-headquartered SDx, as the 2023 Life Sciences CEO of the Year at the ICON Awards.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230502005209/en/
    “I’m deeply gratified with this recognition and honored to be among the top technology and life sciences executives in Maryland,” says Amato.
  • He has assembled a diverse team of passionate and experienced lab technicians, knowledgeable business advisory council members and experienced scientific and medical advisors.

Annals of Clinical Cytology and Pathology Publishes SYNAPS Dx Study, 90% of Physicians Follow Results of DISCERN™, First Highly Accurate Skin Test for Alzheimer’s Disease

Retrieved on: 
Wednesday, February 15, 2023
Mental Health, Managed Care, Medical Devices, Neurology, Science, Family, Genetics, Medical Supplies, Consumer, Biotechnology, Health, Research, Other Health, Women, Pharmaceutical, Seniors, Practice Management, Autopsy, Biomarker, Amato, Pathology, Brain, Memory, Physician, Diagnosis, MI, DISCERN, Clinical trial, Paper, Geriatrics, Software-defined, Disease, FDA, PCP, AD, Dementia, Cognition, Medical imaging, Patient

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the publication of “ Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease in Patients with Suspected Dementia ” in Annals of Clinical Cytology and Pathology.

Key Points: 
  • SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the publication of “ Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease in Patients with Suspected Dementia ” in Annals of Clinical Cytology and Pathology.
  • The study indicates that 90% of physicians would order and routinely use the results of the DISCERN™ test to more accurately diagnose AD, prescribe medications for AD cognitive impairment, refer to a neurologist or prescribe a disease-modifying drug.
  • A majority of clinicians in the study expressed dissatisfaction with the current diagnostic pathway, citing high subjectivity and a significant patient burden.
  • AD-Index: In a clinical trial with AD-Index Assay, patients with autopsy-confirmed AD could be accurately distinguished from patients with non-AD dementias and age-matched controls with 97% sensitivity and 94% specificity.

SYNAPS Dx Demonstrates Physician Burden in Diagnosing Alzheimer's Disease, Value of Highly Accurate Diagnostic Test

Retrieved on: 
Tuesday, January 24, 2023
Biotechnology, Men, Health, Neurology, Consumer, Practice Management, Mental Health, Research, Medical Devices, Genetics, Science, Women, Seniors, Clinical Trials, Autopsy, Amato, Brain, Memory, Physician, DSM-IV codes, Trial of the century, Diagnosis, CT, Fortnight, MRI, DISCERN, PET, Patient, CSF, Software-defined, Disease, CMS, AD, Puncture, Dementia, Amyloid, Cognition, Medical imaging

“Clinicians indicate a significant need for an accurate, readily accessible and less invasive diagnostic tests to inform a definitive diagnosis of AD,” says Frank Amato, CEO and president, SDx.

Key Points: 
  • “Clinicians indicate a significant need for an accurate, readily accessible and less invasive diagnostic tests to inform a definitive diagnosis of AD,” says Frank Amato, CEO and president, SDx.
  • When combined with the treatment burden of bi-weekly administration and cost, it is critical that patients are truly suffering from AD and not another cognitive disease, which will not be treated by AD drugs.
  • DISCERN ™ is the only autopsy validated skin test to identify AD in patients with dementia, even in the presence of mixed dementias.
  • Significantly, the study showed that 8 out of 12 physicians were likely to order the DISCERN test to diagnose patients with suspected AD.

SYNAPS Dx Releases Positive Budget Impact Results for DISCERNTM at International Conference on Aging Diseases and Elderly Care: Alzheimer’s Disease Diagnostic Projected to Save $4+ Million in Three Years

Retrieved on: 
Tuesday, December 13, 2022
Research, Other Health, Consumer, Mental Health, Medical Devices, Genetics, Clinical Trials, Science, Neurology, Biotechnology, Seniors, Health, Other Science, Ageing, Clinical Laboratory, International Conference on Information Systems Security and Privacy, Software-defined, CT, Disease management, PET, Sensitivity and specificity, Conference, Diagnosis, MRI, Dementia, Patient, Amato, Research, PLA, CSF, Disease, Drug development, CLIA, DISCERN, Physician, United, AD, Medicare, Cerebrospinal fluid, Medical device, Medical imaging, Risk management

Results show the DISCERN test can save over $4 million in just three years for a Medicare Advantage plan with one million beneficiaries.

Key Points: 
  • Results show the DISCERN test can save over $4 million in just three years for a Medicare Advantage plan with one million beneficiaries.
  • The DISCERN test is the first and only diagnostic skin test that supports a clinicians definitive diagnosis of AD, even in people recently diagnosed with dementia.
  • DISCERN supports an accurate, definitive diagnosis of AD earlier in the disease and may generate savings for Medicare Advantage plans.
  • SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimers disease (AD).

SYNAPS Dx CEO Frank Amato Presents at HolonIQ, New York: Addresses Importance of Accurately Detecting Causes of Dementia Including Alzheimer’s Disease

Retrieved on: 
Tuesday, September 20, 2022
Mental Health, Research, Seniors, Neurology, Clinical Trials, Managed Care, Health, Consumer, Science, Health Resources and Services Administration, Brain, AD, Biomarker, Association, Company, Cognition, Patient, CEO, Physician, CLIA, EST, Diagnosis, Clinical Laboratory, Amato, Research, Software-defined, DISCERN, Education, Disease, Death, Medical imaging, Dementia

Amato will participate in a fireside chat session titled Detecting AD in Dementia: How validated biomarkers will revolutionize neurodiagnostics?

Key Points: 
  • Amato will participate in a fireside chat session titled Detecting AD in Dementia: How validated biomarkers will revolutionize neurodiagnostics?
  • Amato says, AD dementia currently costs the US health system $290B a year and projections show global cases of the disease could triple by 2050.
  • Currently there are about 5.5 million Americans alone who are afflicted with AD which is the leading cause of dementia.
  • SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimers disease (AD).

Battle Financial, Inc. Selects Finxact to Underpin Ecosystem of Leading Fintech Solution Providers

Retrieved on: 
Thursday, March 10, 2022
Industry, API, Software as a service, EverBank, TIAA, Amato, Eagle County, Colorado, FDIC, Solution, Technology, Ecosystem, Head, COO, Cryptocurrency, Bank, Online shopping

Battle Bank is expected to launch in the second half of this year.

Key Points: 
  • Battle Bank is expected to launch in the second half of this year.
  • The bank is led by two pioneers in the direct banking industry, Frank Trotter and Vincent Amato.
  • "This level of control and agility is a competitive advantage that with Finxact we will be making part of our foundation."
  • "We are honored to be selected by Battle Financial, Inc. as the core platform for Battle Bank's product and service delivery," said Ryan Victor, Chief Revenue Officer, Finxact.

Fountainhead Announces New Senior Vice President

Retrieved on: 
Thursday, January 20, 2022
LTV, University of Mary Washington, Entrepreneurship, Accounting, Small business, SBA, COVID-19, American Express, Knowledge, Growth, Amato, Small Business Administration, GLOBE, United States Air Force, Financial management, Liberty University, 504, Industry, Government, Wells Fargo, Associate, Management, The Fountainhead

ORLANDO, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Fountainhead a Small Business Administration (SBA)-approved nonbank lender for small-to-midsized businesses across the nation today announces the appointment of former SBA District Director Joseph P. Amato as senior vice president.

Key Points: 
  • ORLANDO, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Fountainhead a Small Business Administration (SBA)-approved nonbank lender for small-to-midsized businesses across the nation today announces the appointment of former SBA District Director Joseph P. Amato as senior vice president.
  • A successful entrepreneur and U.S. Air Force veteran, Amato started a small business consulting company which was later acquired.
  • Im eager to leverage my experience with the SBA and beyond to help Fountainhead drive financing opportunities and support to millions of small businesses across America, said Amato.
  • For more information on Fountainhead, or ways to grow your small-to-midsized business, visit FountainheadCC.com .

MasterClass Announces Award-Winning HBO Veteran Len Amato as Chief Content Officer

Retrieved on: 
Wednesday, January 19, 2022
Diamond, Astronaut, HBO, Roku, The Astronaut Farmer, The White House Plumbers, TriBeCa Productions, Emmy Awards, SAN, MasterClass, A&E (TV network), White House, Android TV, Knowledge, Nas, Cinemax, Amato, CEO, Learning, Amazon Fire TV, Temple Grandin, Leadership, HBO Films, The arts, Election recount, The Normal Heart, Work, Grey Gardens, Television, Miniseries, Curriculum, Life, Film, Entertainment, Candelabra

SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- MasterClass , the streaming platform where anyone can learn from the world's best across a wide range of subjects, today announced the appointment of 13-year HBO veteran Len Amato as chief content officer.

Key Points: 
  • SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- MasterClass , the streaming platform where anyone can learn from the world's best across a wide range of subjects, today announced the appointment of 13-year HBO veteran Len Amato as chief content officer.
  • In this role, Amato will head up the content organization and help lead content innovation, strategy and development of class launches.
  • Prior to joining MasterClass, Amato served as president of HBO Films, Miniseries and Cinemax.
  • "Len has been a pioneer in creating premium, original content and I'm thrilled to welcome him to the team," Rogier said.

Workforce Opportunity Services to Discuss Developing, Recruiting and Retaining the Smart City Workforce at Smart Cities Week

Retrieved on: 
Thursday, September 6, 2018
Urban planning, Economic development, Internet of things, Organizational theory, Public policy, Smart city, Sustainable urban planning, Amato, Sustainable community, SMart, Structure

WASHINGTON, Sept. 6, 2018 /PRNewswire/ --Vice President of Business Services for Workforce Opportunity Services (WOS) Tony Amato will join a panel of experts at Smart Cities Week D.C. to discuss cultivating a thriving workforce that meets the demands of a dynamic economy.

Key Points: 
  • WASHINGTON, Sept. 6, 2018 /PRNewswire/ --Vice President of Business Services for Workforce Opportunity Services (WOS) Tony Amato will join a panel of experts at Smart Cities Week D.C. to discuss cultivating a thriving workforce that meets the demands of a dynamic economy.
  • This fourth annual Smart Cities Week D.C., hosted by the Smart Cities Council and MCI, showcases the latest in digital technologies for more livable, sustainable communities.
  • This year's conference theme is Collaboration: the cornerstone of the smart city.
  • Anthony Amato joined Workforce Opportunity Services (WOS) in 2011 and directs all academic operations for the organization.